Top in 2022 CKD: Rosuvastatin shows higher risk of kidney failure vs. atorvastatin

Compared with atorvastatin, rosuvastatin shows higher risks of hematuria, proteinuria and kidney failure in patients with chronic kidney disease.

“We observed a higher risk of hematuria, proteinuria, as well as kidney failure with rosuvastatin use and similar cardiovascular benefits between the rosuvastatin and atorvastatin groups,” Jung-Im Shin, MD, PhD, from the department of epidemiology at Johns Hopkins Bloomberg School of Public Health, said in a press release. “Because rosuvastatin may cause proteinuria and hematuria, especially with [a] high dose, high-dose rosuvastatin may not merit the risk — even if small — particularly for patients with advanced kidney disease.”

It was the top CKD story in 2022.

Another top story covered a study that identified no correlation between aspirin use in patients with CKD and reduced risks for CVD.

In a perspective on the study, Anna Burgner, MD, and Antonette Hernandez, MD, told Healio, “The results of this study do not change current clinical practice. These add to prior hypothesis-generating data, which underscore the need for a large, randomized control trial in patients with CKD.”

Read these and more top stories in CKD below:

Rosuvastatin shows higher risks of hematuria, proteinuria, kidney failure vs. atorvastatin

Compared with atorvastatin, rosuvastatin is associated with increased risks of hematuria, proteinuria and kidney failure with replacement therapy, according to a study. Read more.

Aspirin does not reduce CVD events, progression to kidney failure in patients with CKD

Among patients with chronic kidney disease, aspirin use did not correlate with reduced risks for CVD, progression to kidney failure or major bleeding, according to data published in Kidney Medicine. Read more.

Distance to supermarkets is a risk factor for CKD, hypertension, diabetes development

Researchers identified the distance between a household and a supermarket as a risk factor for chronic kidney disease, hypertension and diabetes development. Read more.

Dual dog, cat ownership may increase risk of peritonitis in patients on PD

Having both a dog and cat in the same household as a patient on peritoneal dialysis may increase the patient’s risk for peritonitis, according to a presenter at the DOPPS Autumn Clinical Update meeting. Read more.

FDA grants approval of Terlivaz injection to treat patients with hepatorenal syndrome

The FDA has announced approval of Terlivaz, a terlipressin injection formulation by Mallinckrodt plc., to treat patients with hepatorenal syndrome with rapid reduction in kidney function. Read more.

Patients with advanced CKD can experience improved quality of life without using dialysis

Patients with advanced chronic kidney disease who choose not to use dialysis can survive many years with improvements to their mental health, in addition to stable physical health and quality of life until late into the illness, data show. Read more.